FDA acknowledges Vivus’s application for Avanafil

MOUNTAIN VIEW, Calif. (AP) — According to an announcement by drugmaker Vivus Inc., the FDA will take until April 29, 2012 to decide upon the company’s drug candidate avanafil, intended to treat impotence.

The FDA acknowledged the marketing application filed on Jun 30, said Vivus. Except in some Asian Pacific Rim countries, the drug developer possesses worldwide rights to avanafil.

On Thursday, Vivus shares declined 34 cents, or 4.1 percent, to $8, and the stock declined 9 cents to $7.91 in after-hours trading.